SAN FRANCISCO, June 12 /PRNewswire/ -- The Hydroxycut(R) controversy - according to noted plaintiff attorney Vance Andrus - has all the characteristics of the "next big one" - the next massive products litigation for plaintiff attorneys. But Iovate Health Sciences Inc., maker of the myriad Hydroxycut weight-loss and muscle-building products, says the FDA's accounting of adverse event reports is "small relative to the many millions of people who have used Hydroxycut products."
HB Litigation Conferences, formerly Mealey's Conferences, is holding a half-day seminar - titled Hydroxycut(R) Litigation Conference - at the Mission Bay Conference Center at the
Designed to educate plaintiff and defense attorneys, companies and insurers, the program is being chaired by Vance Andrus of Andrus Boudreaux PLC in New Orleans and leading California trial attorney Thomas Girardi of Girardi & Keese in Los Angeles.
Annesley DeGaris of Cory Watson Crowder & Degaris P.C. of Birmingham, Ala., will detail the products and ingredients. DeGaris noted on a recent HB teleconference that there were 14 Hydroxycut(R) product lines for weight loss supplements and within those lines, there were 56 variations based on quantity, size and flavor.
Anne Andrews of Andrews & Thornton in Irvine, Calif., will provide an overview of the $23.7 billion dietary supplement industry, including the history of Hydroxycut(R) maker Iovate / Muscletech.
A "Panel Defendants' Forum" will address lessons from Ephedra, distributors, ingredient makers, jurisdiction and consolidation. Moderated by Thomas Clark of Andrus Boudreaux, panelists are John Boundas of Williams Kherkher Hart Boundas in Houston; Annesley DeGaris of Cory, Watson; and Neil Overholtz of Aylstock, Witkin, Kreis & Overholtz in Pensacola, Fla.
|SOURCE HB Litigation Conferences|
Copyright©2009 PR Newswire.
All rights reserved